Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
Healthcare
$14.17 +1.71%
+$0.29 today
- Market cap
- $1.52B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
52W Low $10.42High $25.32
Volume 2.07M
Average 3.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$205.48M
FY 2025 · Annual
Investing Cash Flow
$69.64M
FY 2025 · Annual
-90.8% YoYFinancing Cash Flow
-$168.34M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| Deferred Income Tax | 15.81M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 113.94M | 233.02M | 182.51M | 184.3M | 123.4M |
| Change in Working Capital | (98.17M) | (39.47M) | (481.09M) | (716.61M) | 78.04M |
| Accounts Receivables | (51.65M) | (61.64M) | (185.7M) | (201.66M) | 203.76M |
| Inventory | (83.77M) | (50.78M) | (147.71M) | (395.17M) | (301.09M) |
| Accounts Payables | 23.3M | 147.57M | (50.14M) | 110.65M | 104.27M |
| Other Working Capital | 13.96M | (74.62M) | (97.54M) | (230.42M) | 71.11M |
| Other Non-Cash Items | (94M) | 142.73M | 289.16M | 53.56M | 261.98M |
| Operating Cash Flow | (443.17M) | (325.35M) | (500.99M) | (205.79M) | (205.48M) |
| Capital Expenditures | (38.49M) | (32.25M) | (87.35M) | (146.96M) | (101.97M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (29.99M) | (1.94B) | (2.05B) | (1.1B) | (44.66M) |
| Sales of Investments | 466M | 923.22M | 1.87B | 2B | 469.97M |
| Other Investing Activities | 97.89M | (1.43M) | 90.76M | (10M) | (253.7M) |
| Investing Cash Flow | 495.41M | (1.05B) | (165.8M) | 755.56M | 69.64M |
| Debt Repayment | 0 | 304.17M | 0 | (68K) | (162.59M) |
| Common Stock Issued | 548.53M | 0 | 0 | 0 | 36.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.04M | (71.66M) | 125M | 124.87M | (17.06M) |
| Financing Cash Flow | 561.57M | 232.51M | 125M | 124.81M | (168.34M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 613.81M | (1.14B) | (541.79M) | 674.58M | (304.18M) |
| Free Cash Flow | (481.66M) | (357.6M) | (588.34M) | (352.74M) | (307.45M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$713.4M
+ D&A$44.5M
+ Stock-Based Comp$123.4M
+ Deferred Tax$0
+ Working Capital$78.0M
+ Other Non-Cash$262.0M
= Operating Cash Flow-$205.5M
- Capex-$102.0M
= Free Cash Flow-$307.5M
Analysis
FY2025 free cash flow is -$307.5M. FCF conversion is 43.1% of net income. Operating cash flow was -$205.5M, with capex of -$102.0M. The largest bridge item is Other Non-Cash at $262.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 13F-HR | 13F-HR filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
Does SRPT generate free cash flow?
Sarepta Therapeutics, Inc. (SRPT) generated -$307.45M of free cash flow in fiscal 2025.
How much operating cash flow does SRPT produce?
Operating cash flow was -$205.48M, before capital expenditures of $101.97M.
Continue the stock analysis
Jump to another research area for this company.